Outcomes after double switching from originator Infliximab to biosimilar CT‐P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12‐month prospective cohort study

Noémie Trystram(Université Paris-Est Créteil), Aurélien Amiot(Université Paris-Est Créteil), Véred Abitbol(Hôpital Cochin), Charlotte Gagnière, Julie Assaraf(Université Paris-Est Créteil), Georgia Malamut(Délégation Paris 5), Jenny Tannoury(Centre Hospitalier Universitaire de Lille), Amélie Barré(Université Paris Cité), Mahaut Lecomte(Université Paris Cité), Stanislas Chaussade(Hôpital Cochin), Iradj Sobhani(Université Paris-Est Créteil)
Alimentary Pharmacology & Therapeutics
March 1, 2021
10.1111/apt.16312
Cited by 30

Related Papers

Potential of fecal microbiota for early‐stage detection of colorectal cancer
|Molecular Systems Biology|2014|1.4k
Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia
|New England Journal of Medicine|2011|852
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial1 1The authors thank the women and men who participated in the study, P. E. Douziech for coordination of treatments, and the hospital pharmacists for preparation of the treatments in the trial centers.
|Gastroenterology|2003|395
Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II
|Gastroenterology|2008|378
Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease
|The Journal of Experimental Medicine|2007|310